Blurbs

Bloom Burton Remains a Buy on Aurinia Pharmaceuticals (AUPH)

In a report released on November 3, Prasath Pandurangan from Bloom Burton maintained a Buy rating on Aurinia Pharmaceuticals (AUPHResearch Report), with a price target of $10.50. The company’s shares closed last Friday at $5.15.

According to TipRanks, Pandurangan is an analyst with an average return of -17.5% and a 26.42% success rate.

Currently, the analyst consensus on Aurinia Pharmaceuticals is a Strong Buy with an average price target of $11.63, implying a 125.83% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $28.19 million and a GAAP net loss of $35.52 million. In comparison, last year the company earned a revenue of $6.62 million and had a GAAP net loss of $47.01 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Read More on AUPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed